REFERENCES:

Baselga J. Herceptin alone or in combination with chemotherapy in the treat-ment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 2001;61 Suppl 2:14-21. Abstract

Bell R. Duration of therapy in metastatic breast cancer: Management using Herceptin. Anticancer Drugs 2001;12:561-8. Abstract

Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28:38-44. Abstract

Burstein HJ et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30. Abstract

Cobleigh MA et al. Multinational study of the efficacy and safety of human-ized anti-HER2 monoclonal antibody in women who have HER2- overex-pressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. Abstract

Dieras V et al. Interaction between Herceptin and taxanes. Oncology 2001;61 Suppl 2:43-9. Abstract

Fyfe G et al. Survival benefit of Herceptin (trastuzumab) and chemotherapy in older (age>60) patients. Breast Cancer Res Treat 2001; Abstract 526.

Gerber B et al. Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment. Oncology. 2001;61:271-4. Abstract

Hortobagyi GN. Optimal duration of therapy with trastuzumab. Semin Oncol 2001;28:33-40. Abstract

Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials. Semin Oncol. 2001;28:41-6. Abstract

Leyland-Jones B, Smith I. Role of Herceptin in primary breast cancer: Views from North America and Europe. Oncology 2001;61 Suppl 2:83-91. Abstract

Lueck H-JH-J. Cardiac safety of Herceptin (H) in combination with epiru-bicin (E) plus cyclophosphamide (C): Interim results of a phase II study in patients with metastatic breast cancer. Breast Cancer Res Treat 2001; Abstract 439.

Mass R et al. Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit. Breast Cancer Res Treat 2001; Abstract 522.

Mass R et al. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. Breast Cancer Res Treat 2001; Abstract 18.

Meden H et al. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study. Anticancer Res 2001;21:1301-5. Abstract

Miller KD et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001;15:38-40. Abstract

Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001;28:1-12. Abstract

O'Shaughnessy JA et al. Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: Preliminary results of a phase II study. Breast Cancer Res Treat 2001; Abstract 523.

Paik S, Park C. HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin Oncol 2001;28:332-5. Abstract

Perez EA. The role of adjuvant monoclonal antibody therapy for breast can-cer: rationale and new studies. Curr Oncol Rep 2001;3:516-22. Abstract

Robert NJ et al. Toxicity profiles: A comparative study of Herceptin (trastuzumab) and Taxol (paclitaxel) versus Herceptin, Taxol, and carbo-platin in HER-2 positive patients with advanced breast cancer. Breast Cancer Res Treat 2001; Abstract 529.

Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95. Abstract

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. Abstract

Sledge GW et al. Pilot trial of paclitaxel-Herceptin adjuvant therapy for early stage breast cancer (E2198). Breast Cancer Res Treat 2001; Abstract 4.

Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Semin Oncol 2001;28:20-7. Abstract

Tripathy D et al. Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial. Breast Cancer Res Treat 2001; Abstract 525.

Vogel C et al. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report. Eur J Cancer. 2001;37 Suppl 1:S25-9. Abstract

Vogel CL et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:37-42. Abstract

Vogel CL et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc ASCO 2001; Abstract 86.

Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology. 2001;61 Suppl 2:50-7. Abstract

Back | Top of Page